Allergan rejects Valeant Pharma’s ‘cut and slash’ takeover

[Reuters – UK Focus] – * Allergan (NYSE: AGN – news) says offer undervalues company * Allergan expects EPS growth of 20-25 percent (Adds Ackman’s fund asking for Allergan shareholder list, paragraphs 10-11) May 12 (Reuters) – U.S. drugmaker Allergan Inc more

View todays social media effects on BLK

View the latest stocks trending across Twitter. Click to view dashboard

See who BlackRock is hiring next, click here to view